vs
Side-by-side financial comparison of Celanese Corp (CE) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $2.2B, roughly 1.1× Celanese Corp). Zoetis runs the higher net margin — 25.3% vs 0.6%, a 24.6% gap on every dollar of revenue. On growth, Zoetis posted the faster year-over-year revenue change (3.0% vs -7.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $168.0M). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs -8.1%).
Celanese Corporation, formerly known as Hoechst Celanese, is an American technology and specialty materials company headquartered in Irving, Texas. It is a Fortune 500 corporation. The company is the world's leading producer of acetic acid, producing about 1.95 million tonnes per year, representing approximately 20% of global production. Celanese is also the world's largest producer of vinyl acetate monomer (VAM).
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
CE vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.2B | $2.4B |
| Net Profit | $14.0M | $603.0M |
| Gross Margin | 19.1% | 70.2% |
| Operating Margin | 4.0% | 31.9% |
| Net Margin | 0.6% | 25.3% |
| Revenue YoY | -7.0% | 3.0% |
| Net Profit YoY | 100.7% | 3.8% |
| EPS (diluted) | $0.13 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.2B | $2.4B | ||
| Q3 25 | $2.4B | $2.4B | ||
| Q2 25 | $2.5B | $2.5B | ||
| Q1 25 | $2.4B | $2.2B | ||
| Q4 24 | $2.4B | $2.3B | ||
| Q3 24 | $2.6B | $2.4B | ||
| Q2 24 | $2.7B | $2.4B | ||
| Q1 24 | $2.6B | $2.2B |
| Q4 25 | $14.0M | $603.0M | ||
| Q3 25 | $-1.4B | $721.0M | ||
| Q2 25 | $199.0M | $718.0M | ||
| Q1 25 | $-21.0M | $631.0M | ||
| Q4 24 | $-1.9B | $581.0M | ||
| Q3 24 | $116.0M | $682.0M | ||
| Q2 24 | $155.0M | $624.0M | ||
| Q1 24 | $121.0M | $599.0M |
| Q4 25 | 19.1% | 70.2% | ||
| Q3 25 | 21.5% | 71.5% | ||
| Q2 25 | 21.1% | 73.6% | ||
| Q1 25 | 19.9% | 72.0% | ||
| Q4 24 | 22.7% | 69.5% | ||
| Q3 24 | 23.5% | 70.6% | ||
| Q2 24 | 24.2% | 71.7% | ||
| Q1 24 | 21.2% | 70.6% |
| Q4 25 | 4.0% | 31.9% | ||
| Q3 25 | -52.7% | 37.0% | ||
| Q2 25 | 9.2% | 36.7% | ||
| Q1 25 | 7.0% | 36.5% | ||
| Q4 24 | -59.3% | 31.6% | ||
| Q3 24 | 9.4% | 36.6% | ||
| Q2 24 | 9.4% | 33.0% | ||
| Q1 24 | 8.0% | 34.1% |
| Q4 25 | 0.6% | 25.3% | ||
| Q3 25 | -56.1% | 30.0% | ||
| Q2 25 | 7.9% | 29.2% | ||
| Q1 25 | -0.9% | 28.4% | ||
| Q4 24 | -80.8% | 25.1% | ||
| Q3 24 | 4.4% | 28.6% | ||
| Q2 24 | 5.8% | 26.4% | ||
| Q1 24 | 4.6% | 27.4% |
| Q4 25 | $0.13 | $1.37 | ||
| Q3 25 | $-12.39 | $1.63 | ||
| Q2 25 | $1.81 | $1.61 | ||
| Q1 25 | $-0.19 | $1.41 | ||
| Q4 24 | $-17.50 | $1.29 | ||
| Q3 24 | $1.06 | $1.50 | ||
| Q2 24 | $1.41 | $1.37 | ||
| Q1 24 | $1.10 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | $11.4B | — |
| Stockholders' EquityBook value | $4.0B | $3.3B |
| Total Assets | $21.7B | $15.5B |
| Debt / EquityLower = less leverage | 2.81× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | — | $2.0B |
| Q4 25 | $11.4B | — | ||
| Q3 25 | $11.7B | — | ||
| Q2 25 | $12.7B | — | ||
| Q1 25 | $12.4B | — | ||
| Q4 24 | $11.1B | — | ||
| Q3 24 | $11.3B | — | ||
| Q2 24 | $11.1B | — | ||
| Q1 24 | $11.0B | — |
| Q4 25 | $4.0B | $3.3B | ||
| Q3 25 | $4.0B | $5.4B | ||
| Q2 25 | $5.3B | $5.0B | ||
| Q1 25 | $5.2B | $4.7B | ||
| Q4 24 | $5.2B | $4.8B | ||
| Q3 24 | $7.3B | $5.2B | ||
| Q2 24 | $7.2B | $5.0B | ||
| Q1 24 | $7.1B | $5.1B |
| Q4 25 | $21.7B | $15.5B | ||
| Q3 25 | $22.2B | $15.2B | ||
| Q2 25 | $23.7B | $14.5B | ||
| Q1 25 | $23.2B | $14.1B | ||
| Q4 24 | $22.9B | $14.2B | ||
| Q3 24 | $25.9B | $14.4B | ||
| Q2 24 | $25.8B | $14.2B | ||
| Q1 24 | $26.0B | $14.3B |
| Q4 25 | 2.81× | — | ||
| Q3 25 | 2.95× | — | ||
| Q2 25 | 2.41× | — | ||
| Q1 25 | 2.39× | — | ||
| Q4 24 | 2.14× | — | ||
| Q3 24 | 1.56× | — | ||
| Q2 24 | 1.54× | — | ||
| Q1 24 | 1.56× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $252.0M | $893.0M |
| Free Cash FlowOCF − Capex | $168.0M | $732.0M |
| FCF MarginFCF / Revenue | 7.6% | 30.7% |
| Capex IntensityCapex / Revenue | 3.8% | 6.7% |
| Cash ConversionOCF / Net Profit | 18.00× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $803.0M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $252.0M | $893.0M | ||
| Q3 25 | $447.0M | $938.0M | ||
| Q2 25 | $410.0M | $486.0M | ||
| Q1 25 | $37.0M | $587.0M | ||
| Q4 24 | $494.0M | $905.0M | ||
| Q3 24 | $79.0M | $951.0M | ||
| Q2 24 | $292.0M | $502.0M | ||
| Q1 24 | $101.0M | $595.0M |
| Q4 25 | $168.0M | $732.0M | ||
| Q3 25 | $383.0M | $805.0M | ||
| Q2 25 | $317.0M | $308.0M | ||
| Q1 25 | $-65.0M | $438.0M | ||
| Q4 24 | $389.0M | $689.0M | ||
| Q3 24 | $-9.0M | $784.0M | ||
| Q2 24 | $187.0M | $370.0M | ||
| Q1 24 | $-36.0M | $455.0M |
| Q4 25 | 7.6% | 30.7% | ||
| Q3 25 | 15.8% | 33.5% | ||
| Q2 25 | 12.5% | 12.5% | ||
| Q1 25 | -2.7% | 19.7% | ||
| Q4 24 | 16.4% | 29.7% | ||
| Q3 24 | -0.3% | 32.8% | ||
| Q2 24 | 7.1% | 15.7% | ||
| Q1 24 | -1.4% | 20.8% |
| Q4 25 | 3.8% | 6.7% | ||
| Q3 25 | 2.6% | 5.5% | ||
| Q2 25 | 3.7% | 7.2% | ||
| Q1 25 | 4.3% | 6.7% | ||
| Q4 24 | 4.4% | 9.3% | ||
| Q3 24 | 3.3% | 7.0% | ||
| Q2 24 | 4.0% | 5.6% | ||
| Q1 24 | 5.2% | 6.4% |
| Q4 25 | 18.00× | 1.48× | ||
| Q3 25 | — | 1.30× | ||
| Q2 25 | 2.06× | 0.68× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | 0.68× | 1.39× | ||
| Q2 24 | 1.88× | 0.80× | ||
| Q1 24 | 0.83× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CE
| Engineered Materials | $1.3B | 58% |
| Acetyl Chain | $940.0M | 43% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
